Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Emerging role of GLP-1 agonists in obesity: a comprehensive review of randomised controlled trials
Obesity is a chronic disease with high prevalence and associated comorbidities, making it a
growing global concern. These comorbidities include type 2 diabetes, hypertension …
growing global concern. These comorbidities include type 2 diabetes, hypertension …
Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics
The obesity epidemic is closely associated with the rising prevalence and severity of
nonalcoholic fatty liver disease (NAFLD): obesity has been linked not only with simple …
nonalcoholic fatty liver disease (NAFLD): obesity has been linked not only with simple …
Long-term efficacy and safety of anti-obesity treatment: where do we stand?
YJ Tak, SY Lee - Current obesity reports, 2021 - Springer
Abstract Purpose of Review As a chronic and relapsing disease, obesity impairs metabolism
and causes cardiovascular diseases. Although behavioral modification is important for the …
and causes cardiovascular diseases. Although behavioral modification is important for the …
Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical …
L He, J Wang, F **, N Yang, J Huang… - JAMA internal …, 2022 - jamanetwork.com
Importance Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been widely
recommended for glucose control and cardiovascular risk reduction in patients with type 2 …
recommended for glucose control and cardiovascular risk reduction in patients with type 2 …
Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study …
The American Diabetes Association and the European Association for the Study of Diabetes
convened a panel to update the prior position statements, published in 2012 and 2015, on …
convened a panel to update the prior position statements, published in 2012 and 2015, on …
Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the …
Abstract The American Diabetes Association and the European Association for the Study of
Diabetes convened a panel to update the prior position statements, published in 2012 and …
Diabetes convened a panel to update the prior position statements, published in 2012 and …
GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
X Ma, Z Liu, I Ilyas, PJ Little, D Kamato… - … journal of biological …, 2021 - pmc.ncbi.nlm.nih.gov
Type 2 diabetes mellitus (T2DM) is closely associated with cardiovascular diseases (CVD),
including atherosclerosis, hypertension and heart failure. Some anti-diabetic medications …
including atherosclerosis, hypertension and heart failure. Some anti-diabetic medications …
Gastrointestinal adverse events associated with semaglutide: a pharmacovigilance study based on FDA adverse event reporting system
Y Shu, X He, P Wu, Y Liu, Y Ding, Q Zhang - Frontiers in public health, 2022 - frontiersin.org
Background Semaglutide was approved for treatment of type 2 diabetes mellitus (T2DM)
and chronic weight management in obesity or overweight adults. However, real-world data …
and chronic weight management in obesity or overweight adults. However, real-world data …
The relationship between diabetes mellitus and cancers and its underlying mechanisms
B Zhu, S Qu - Frontiers in Endocrinology, 2022 - frontiersin.org
Epidemiological studies suggest associations between diabetes mellitus and some cancers.
The risk of a number of cancers appears to be increased in diabetes mellitus. On the other …
The risk of a number of cancers appears to be increased in diabetes mellitus. On the other …
Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus …
Due to their cardiovascular protective effect, glucagon-like peptide-1 receptor agonists (GLP-
1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) represent breakthrough …
1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) represent breakthrough …